NO975331D0 - Use of R-enantiomer of N-propargyl-1-aminoindan salts and compositions thereof - Google Patents
Use of R-enantiomer of N-propargyl-1-aminoindan salts and compositions thereofInfo
- Publication number
- NO975331D0 NO975331D0 NO975331A NO975331A NO975331D0 NO 975331 D0 NO975331 D0 NO 975331D0 NO 975331 A NO975331 A NO 975331A NO 975331 A NO975331 A NO 975331A NO 975331 D0 NO975331 D0 NO 975331D0
- Authority
- NO
- Norway
- Prior art keywords
- propargyl
- enantiomer
- compositions
- aminoindan
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
- C07C211/30—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring the six-membered aromatic ring being part of a condensed ring system formed by two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/446,439 US5744500A (en) | 1990-01-03 | 1995-05-22 | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
PCT/US1996/007465 WO1996037199A1 (en) | 1995-05-22 | 1996-05-22 | Use of r-enantiomer of n-propargyl-1-aminoindan, salts, and compositions thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
NO975331D0 true NO975331D0 (en) | 1997-11-20 |
NO975331L NO975331L (en) | 1998-01-20 |
Family
ID=23772591
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO975331A NO975331L (en) | 1995-05-22 | 1997-11-20 | Use of R-enantiomer of N-propargyl-1-aminoindan salts and compositions thereof |
Country Status (22)
Country | Link |
---|---|
US (6) | US5744500A (en) |
EP (1) | EP0828485A4 (en) |
JP (1) | JP3341898B2 (en) |
KR (1) | KR100412154B1 (en) |
CN (1) | CN1096853C (en) |
AU (1) | AU699090B2 (en) |
BR (1) | BR9608733A (en) |
CA (1) | CA2221458A1 (en) |
CZ (1) | CZ288724B6 (en) |
EE (1) | EE03741B1 (en) |
HK (1) | HK1015269A1 (en) |
HU (1) | HUP9901629A3 (en) |
IL (1) | IL118247A (en) |
LT (1) | LT4455B (en) |
LV (1) | LV12083B (en) |
MX (1) | MX9708977A (en) |
NO (1) | NO975331L (en) |
NZ (1) | NZ308866A (en) |
PL (1) | PL184124B1 (en) |
RU (1) | RU2203653C2 (en) |
SK (1) | SK283675B6 (en) |
WO (1) | WO1996037199A1 (en) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
US5877218A (en) * | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
US5726969A (en) * | 1994-12-28 | 1998-03-10 | Matsushita Electric Industrial Co., Ltd. | Optical recording medium having dual information surfaces |
IL118836A (en) | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
GB9715082D0 (en) * | 1997-07-17 | 1997-09-24 | Scherer Ltd R P | Treatment of attention deficit hyperactivity disorder and narcolepsy |
US6232326B1 (en) | 1998-07-14 | 2001-05-15 | Jodi A. Nelson | Treatment for schizophrenia and other dopamine system dysfunctions |
AU775885B2 (en) | 1999-10-27 | 2004-08-19 | Teva Pharmaceutical Industries Ltd. | Use of 1-aminoindan derivatives for treatment of mania in bipolar mood disorder |
ATE427745T1 (en) | 2001-11-05 | 2009-04-15 | Krele Pharmaceuticals Llc | COMPOSITIONS AND METHODS FOR INCREASE COMPLIANCE WITH THERAPIES USING ALDEHYDE DEHYDROGENASE INHIBITORS AND FOR TREATING ALCOHOLSM |
US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
US8058442B2 (en) * | 2002-11-07 | 2011-11-15 | Technion Research And Development Foundation Ltd. | Neuroprotective iron chelators and pharmaceutical compositions comprising them |
AU2003290838A1 (en) * | 2002-11-15 | 2004-06-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
US20040176430A1 (en) * | 2002-11-21 | 2004-09-09 | Jeffrey Sterling | Propargyl-trifluoromethoxy-amino-benzothiazole derivatives |
CN1605336A (en) | 2003-10-10 | 2005-04-13 | 中国医学科学院药物研究所 | Application of L-butylphthalide in the process for preparing cerebral infarction preventing and treating medicine |
US8097608B2 (en) * | 2003-11-25 | 2012-01-17 | Technion Research And Development Foundation Ltd. | Methods for treatment of cardiovascular disorders and diseases |
EP1686973A4 (en) * | 2003-11-25 | 2009-03-25 | Technion Res & Dev Foundation | Compositions and methods for treatment of cardiovascular disorders and diseases |
JP2005232148A (en) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | Use of propargylamine as neuroprotective agent |
US20050197365A1 (en) * | 2004-02-27 | 2005-09-08 | Jeffrey Sterling | Diamino thiazoloindan derivatives and their use |
US20060018957A1 (en) * | 2004-07-26 | 2006-01-26 | Lerner E I | Pharmaceutical dosage forms including rasagiline |
WO2006014968A2 (en) * | 2004-07-27 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
US20060025446A1 (en) * | 2004-07-27 | 2006-02-02 | Jeffrey Sterling | Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
US20100167983A1 (en) * | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
EP2332408B1 (en) | 2005-02-17 | 2013-11-13 | Biogen Idec MA Inc. | Treating neurological disorders |
PL1848415T3 (en) * | 2005-02-17 | 2013-10-31 | Teva Pharma | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
CA2901244A1 (en) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
WO2006091836A1 (en) * | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Formulations of ladostigil tartrate |
ES2432564T3 (en) | 2005-05-10 | 2013-12-04 | Biogen Idec Ma Inc. | Treatment and evaluation of inflammatory disorders |
EP1888056A4 (en) * | 2005-06-01 | 2008-09-03 | Teva Pharma | Use of ladostigil for the treatment of multiple sclerosis |
FR2886549B1 (en) * | 2005-06-06 | 2007-09-07 | Biocodex | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CEREBRAL EDEMA |
US8263655B2 (en) * | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
AU2006316585B2 (en) * | 2005-11-17 | 2012-09-20 | Teva Pharmaceutical Industries, Ltd. | Methods for isolating propargylated aminoindans |
US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
CA2634166C (en) * | 2005-12-09 | 2016-03-29 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
US20070135518A1 (en) * | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
US20110047685A1 (en) * | 2006-02-16 | 2011-03-03 | Ferrara Vincent R | Impact energy management method and system |
ES2551481T3 (en) | 2006-02-21 | 2015-11-19 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multisystemic atrophy |
TW200744576A (en) * | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
NZ571591A (en) * | 2006-04-03 | 2011-09-30 | Teva Pharma | Use of rasagiline for the treatment of restless legs syndrome |
CN101062897B (en) * | 2006-04-25 | 2011-11-23 | 重庆医药工业研究院有限责任公司 | Improved process for preparing 2,3-dihydro-1H-indenes-1-amine and derivative thereof |
EP1892233A1 (en) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | New salts of the active component rasagiline |
AU2007334428B2 (en) * | 2006-12-14 | 2014-05-29 | Teva Pharmaceutical Industries, Ltd. | Crystalline solid rasagiline base |
BRPI0718339A2 (en) * | 2006-12-14 | 2014-02-18 | Teva Pharma | COMPOSITION, COMPOSITION, PHARMACEUTICAL COMPOSITION AND RASAGILINE TANATE MANUFACTURING PROCESS |
EP1987816A1 (en) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate of a rasagiline salt with a water-soluble inactive ingredient |
US20090062400A1 (en) * | 2007-09-05 | 2009-03-05 | Laurence Oron | Method of treating glaucoma using rasagiline |
US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
CN101909438A (en) * | 2008-01-11 | 2010-12-08 | 泰华制药工业有限公司 | Rasagiline formulations, their preparation and use |
WO2009118657A2 (en) * | 2008-03-28 | 2009-10-01 | Medichem, S.A. | Polymorphic form of an aminoindan mesylate derivative |
CN102203053B (en) * | 2008-06-02 | 2015-11-25 | 基因里克斯(英国)有限公司 | Improving one's methods for the preparation of amine |
CA2723869C (en) * | 2008-06-02 | 2013-07-16 | Generics [Uk] Limited | A process for the preparation of enantiomerically pure amines |
ES2389353T3 (en) * | 2008-06-10 | 2012-10-25 | Teva Pharmaceutical Industries Ltd. | Rasagiline soft gelatin capsules |
BRPI0909894A2 (en) * | 2008-06-13 | 2015-07-28 | Teva Pharma | "method of reducing the rate of progression of parkinson's disease in an early stage parkinson's disease patient, method of reducing the rate of progression of parkinson's disease, method of delaying the need for symptomatic antiparkinsonian therapy in a patient of early-stage parkinson's, risk-reduction method for a parkinson's disease patient requiring antiparkinsonian therapy, early-stage parkinson's disease reduction method, functional-decline method for a patient with Parkinson's disease, a patient's treatment method that displays early signs of parkinson's disease, fatigue reduction method in an early-stage parkinson's disease patient, method of reducing the rate of clinical progression, and treatment of symptoms of parkinsonian disease. parkinson in a patient with parkinson's disease, rasagiline or a pharmaceutically acceptable salt of rasagiline, pharmaceutical composition. |
NZ589547A (en) * | 2008-06-19 | 2013-03-28 | Teva Pharma | Dried rasagiline base having a water content less than 0.5 % by weight |
CA2727021A1 (en) * | 2008-06-19 | 2009-12-23 | Teva Pharmaceutical Industries Ltd. | Process for purifying rasagiline base |
EA201170181A1 (en) | 2008-07-11 | 2011-08-30 | Синтон Бв | POLYMORPHIC FORMS OF RAZAGILINA HYDROCHLORIDE |
EP2321258A1 (en) * | 2008-07-30 | 2011-05-18 | Generics [UK] Limited | Polymorphic form of rasagiline mesylate |
US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
EP2218444A3 (en) | 2009-01-23 | 2010-08-25 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline formulation |
JP2012523393A (en) * | 2009-04-09 | 2012-10-04 | エム・エス・ディー・オス・ベー・フェー | Indane derivatives |
PL2451771T3 (en) | 2009-07-09 | 2014-12-31 | Ratiopharm Gmbh | Salts of rasagiline and pharmaceutical preparations thereof |
CN102048717B (en) † | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | Stable rasagiline composition |
EP2325159A1 (en) | 2009-11-24 | 2011-05-25 | LEK Pharmaceuticals d.d. | Novel salts of rasagiline |
US8741962B2 (en) * | 2009-11-26 | 2014-06-03 | Usv Limited | Process for preparation of Rasagiline and salts thereof |
EP2515891A4 (en) | 2009-12-22 | 2013-06-05 | Teva Pharma | 3-keto-n-propargyl-1-aminoindan |
LT2531181T (en) | 2010-02-03 | 2019-07-10 | Pharma Two B Ltd. | Extended release formulations of rasagiline and uses thereof |
EA023786B1 (en) | 2010-04-30 | 2016-07-29 | ТЕЙКОКУ ФАРМА ЮЭсЭй, ИНК. | Propynylaminoindan transdermal compositions |
AU2011282716A1 (en) | 2010-07-27 | 2013-03-14 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
CA2806740A1 (en) | 2010-07-27 | 2012-02-02 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
EP2611440B1 (en) | 2010-09-01 | 2017-02-01 | Tonix Pharmaceuticals, Inc. | Treatment for cocaine addiction |
AU2011320611A1 (en) | 2010-10-26 | 2013-06-13 | Teva Pharmaceutical Industries Ltd. | Deuterium enriched rasagiline |
WO2012125020A1 (en) * | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
EP2688561B1 (en) | 2011-03-24 | 2018-08-22 | Teikoku Pharma USA, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
BR112014008552A2 (en) | 2011-10-10 | 2017-04-18 | Teva Pharma | r (+) - n-methylpropargylaminoindane |
KR20140090996A (en) | 2011-10-10 | 2014-07-18 | 테바 파마슈티컬 인더스트리즈 리미티드 | R(+)-n-formyl-propargyl-aminoindan |
US9913812B2 (en) | 2011-11-09 | 2018-03-13 | Teikoku Pharma Usa, Inc. | Methods for the treatment of skin neoplasms |
MX343986B (en) | 2012-03-21 | 2016-12-01 | Synthon Bv | Stabilized pharmaceutical compositions comprising rasagiline salts. |
WO2013175493A1 (en) | 2012-04-09 | 2013-11-28 | Cadila Healthcare Limited | Stable oral pharmaceutical compositions |
BR112015003451A2 (en) | 2012-08-17 | 2017-07-04 | Teva Pharma | parenteral formulation of rasagiline |
JP6050896B2 (en) | 2012-11-02 | 2016-12-21 | テイコク ファーマ ユーエスエー インコーポレーテッド | Propinylaminoindan transdermal composition |
ES2524865T1 (en) * | 2013-02-06 | 2014-12-15 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate-release tablets |
ES2502140T1 (en) * | 2013-02-06 | 2014-10-02 | Galenicum Health S.L. | Rasagiline hemitartrate immediate-release tablets |
CN105163729A (en) * | 2013-03-13 | 2015-12-16 | N到B有限公司 | Methods, compositions and devices for treatment of motor and depression symptoms associated with parkinson's disease |
CN103804200B (en) * | 2014-02-21 | 2015-04-29 | 常州市第四制药厂有限公司 | Preparation method of rasagiline and analogue thereof |
WO2020214886A1 (en) * | 2019-04-17 | 2020-10-22 | Vici Health Sciences LLC | Liquid pharmaceutical compositions |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3201470A (en) * | 1965-08-17 | Chsx c cech | ||
US513244A (en) * | 1894-01-23 | Island | ||
US3253037A (en) * | 1962-06-19 | 1966-05-24 | Ciba Geigy Corp | N-2-alkynyl-amino-benzocylo-alkanes |
GB1187017A (en) * | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
GB1037014A (en) | 1963-08-02 | 1966-07-20 | Aspro Nicholas Ltd | Derivatives of 1-aminoindane |
US3513249A (en) * | 1968-12-24 | 1970-05-19 | Ideal Ind | Explosion connector with improved insulating means |
GB1548022A (en) | 1976-10-06 | 1979-07-04 | Wyeth John & Brother Ltd | Pharmaceutial dosage forms |
DE3779500T2 (en) | 1986-06-10 | 1993-01-21 | Chiesi Farma Spa | LEVODOPA METHYL ESTER CONTAINING PHARMACEUTICAL COMPOSITIONS, THEIR PRODUCTION AND THERAPEUTIC USE. |
ES2052593T3 (en) | 1986-08-21 | 1994-07-16 | Roussel Uclaf | PROCEDURE FOR PREPARING DERIVATIVES OF INDANO. |
HU197510B (en) | 1986-12-19 | 1989-04-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick |
US4855326A (en) * | 1987-04-20 | 1989-08-08 | Fuisz Pharmaceutical Ltd. | Rapidly dissoluble medicinal dosage unit and method of manufacture |
ZA885824B (en) | 1987-08-14 | 1989-04-26 | Merrell Dow Pharma | Novel antidepressants |
FR2626877B1 (en) | 1988-02-05 | 1991-04-05 | Delalande Sa | ALKYLIC OR BENZYL ETHERS OF PHENOL, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS |
HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
GB8909793D0 (en) | 1989-04-28 | 1989-06-14 | Beecham Group Plc | Pharmaceutical formulation |
US5079018A (en) * | 1989-08-14 | 1992-01-07 | Neophore Technologies, Inc. | Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs |
CA2067123A1 (en) | 1989-09-25 | 1991-03-26 | Esther M. Sternberg | Evaluative means for detecting inflammatory reactivity and for predicting response to stress |
WO1991004757A1 (en) | 1989-10-02 | 1991-04-18 | Cima Labs, Inc. | Effervescent dosage form and method of administering same |
FR2655044B1 (en) | 1989-11-24 | 1995-03-03 | Delalande Sa | DERIVATIVES OF (HETERO) ARYLMETHYLOXY-4 PHENYL TETRAZOLE AND OXADIAZOLE, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION. |
JPH03176457A (en) | 1989-12-04 | 1991-07-31 | Nippon Paint Co Ltd | Novel propargyl compound, its production and coating material containing the same compound |
IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
CA2039742A1 (en) | 1990-04-23 | 1991-10-24 | Andrew B. Dennis | Tablet composition and method for problem pharmaceutical materials |
US5169868A (en) | 1991-03-01 | 1992-12-08 | University Of Saskatchewan | Aliphatic propargylamines as specific mao-b inhibitors |
US5444095A (en) * | 1991-04-04 | 1995-08-22 | University Of Toronto, Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
US5767164A (en) * | 1991-04-04 | 1998-06-16 | Innovations Foundation | Use of deprenyl to rescue damaged nerve cells |
US5844003A (en) * | 1991-04-04 | 1998-12-01 | Innovations Foundation | Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function |
IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
ATE172637T1 (en) * | 1991-12-24 | 1998-11-15 | Yamanouchi Pharma Co Ltd | INTRABUCCAL DISINTEGRATION PREPARATION AND PRODUCTION THEREOF |
US5298261A (en) * | 1992-04-20 | 1994-03-29 | Oregon Freeze Dry, Inc. | Rapidly distintegrating tablet |
AU4534593A (en) | 1992-06-12 | 1994-01-04 | Affymax Technologies N.V. | Compositions and methods for enhanced drug delivery |
SE501848C2 (en) | 1992-11-18 | 1995-06-06 | Kvaerner Pulping Tech | Method to cook pulp continuously at constant temperature |
IL111240A (en) | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
IL112779A (en) | 1994-03-01 | 1999-11-30 | Gergely Gerhard | Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation |
CZ297382B6 (en) | 1995-03-02 | 2006-11-15 | R.P. Scherer Limited | Rapidly dispersing oral solid dosage form of pharmaceutical for the treatment of Parkinson's disease |
IL115357A (en) | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
EP1052983A2 (en) * | 1998-01-27 | 2000-11-22 | Thomas N. Thomas | Use of an mao-a or mao-b inhibitor for the treatment of vascular disorders |
FI104042B (en) * | 1998-09-29 | 1999-11-15 | Aaro Kiuru | Procedure for measuring lung perfusion |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
MXPA03012041A (en) * | 2001-07-04 | 2004-03-26 | Sun Pharmaceutical Ind Ltd | Gastric retention controlled drug delivery system. |
US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
US20040166159A1 (en) * | 2002-05-29 | 2004-08-26 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa |
US20060009483A1 (en) * | 2002-05-31 | 2006-01-12 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
US20040115254A1 (en) * | 2002-09-06 | 2004-06-17 | Genteric, Inc. | Microcapsules and methods of use |
AU2003290838A1 (en) * | 2002-11-15 | 2004-06-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
CA2901244A1 (en) * | 2005-02-23 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
-
1995
- 1995-05-22 US US08/446,439 patent/US5744500A/en not_active Expired - Lifetime
-
1996
- 1996-05-14 IL IL11824796A patent/IL118247A/en not_active IP Right Cessation
- 1996-05-22 CN CN96195710A patent/CN1096853C/en not_active Expired - Fee Related
- 1996-05-22 PL PL96323470A patent/PL184124B1/en not_active IP Right Cessation
- 1996-05-22 NZ NZ308866A patent/NZ308866A/en not_active IP Right Cessation
- 1996-05-22 CA CA002221458A patent/CA2221458A1/en not_active Abandoned
- 1996-05-22 EP EP96920401A patent/EP0828485A4/en not_active Ceased
- 1996-05-22 MX MX9708977A patent/MX9708977A/en unknown
- 1996-05-22 SK SK1574-97A patent/SK283675B6/en unknown
- 1996-05-22 CZ CZ19973699A patent/CZ288724B6/en not_active IP Right Cessation
- 1996-05-22 RU RU97121002/14A patent/RU2203653C2/en not_active IP Right Cessation
- 1996-05-22 US US08/952,705 patent/US6316504B1/en not_active Expired - Lifetime
- 1996-05-22 HU HU9901629A patent/HUP9901629A3/en unknown
- 1996-05-22 EE EE9700310A patent/EE03741B1/en not_active IP Right Cessation
- 1996-05-22 KR KR1019970708371A patent/KR100412154B1/en not_active IP Right Cessation
- 1996-05-22 BR BR9608733-1A patent/BR9608733A/en not_active Application Discontinuation
- 1996-05-22 JP JP53584496A patent/JP3341898B2/en not_active Expired - Fee Related
- 1996-05-22 WO PCT/US1996/007465 patent/WO1996037199A1/en not_active Application Discontinuation
- 1996-05-22 AU AU58723/96A patent/AU699090B2/en not_active Expired
-
1997
- 1997-11-20 NO NO975331A patent/NO975331L/en not_active Application Discontinuation
- 1997-12-22 LT LT97-200A patent/LT4455B/en not_active IP Right Cessation
-
1998
- 1998-01-20 LV LVP-97-267A patent/LV12083B/en unknown
-
1999
- 1999-01-27 HK HK99100353A patent/HK1015269A1/en not_active IP Right Cessation
-
2001
- 2001-10-26 US US10/016,268 patent/US6630514B2/en not_active Expired - Fee Related
-
2002
- 2002-11-27 US US10/305,478 patent/US6956060B2/en not_active Expired - Fee Related
-
2005
- 2005-06-17 US US11/155,864 patent/US20060094783A1/en not_active Abandoned
-
2006
- 2006-11-10 US US11/595,726 patent/US20070100001A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO975331D0 (en) | Use of R-enantiomer of N-propargyl-1-aminoindan salts and compositions thereof | |
DE19681287T1 (en) | Oral formulation of 2-methylthienobenzodiazepine | |
NO972972L (en) | Compositions for the treatment of dermatological disorders and methods for their use | |
EE03486B1 (en) | Pyrazol-4-yl-benzoyl derivatives and their use as herbicides | |
NO2008002I1 (en) | Protioconazole and its salts | |
NO982311D0 (en) | Compositions and methods for the prevention and treatment of oral mucositis | |
DK0804078T3 (en) | Composition and use thereof | |
NO962491D0 (en) | Oral formulations of S (+) - etodolac | |
NO970198L (en) | Use of glyceryl triacetate for the treatment of onychomycoses | |
NO20001717D0 (en) | Serotonin-containing formulation for oral administration and use of the same | |
DE69614038T2 (en) | Alkenylcyclohexane derivatives and liquid crystalline compositions | |
FI960425A (en) | Use of phenylcyclohexylcarboxylic acid amides | |
NO982100D0 (en) | Peptide derivatives of Dolastatin 15 and their use | |
EE9800054A (en) | Pyrazol-4-yl-benzoyl derivatives and their use as herbicides | |
NO992384D0 (en) | Multivalent salts of pyridostigmine and related compounds | |
DK0869952T3 (en) | Derivatives of 5-naphthalen-1-yl-1,3-dioxanes, preparation and therapeutic use thereof | |
KR970000226A (en) | Oral Formulations of S-Ibuprofen | |
NO981741D0 (en) | Salts of N- (4-oxo-2- (1H-tertrazolyl-5-yl) -4H-1-benzopyran-8-yl) -4- (4-phenylbutoxy) benzamide) | |
NO944386L (en) | Preparation and use of tetrazole derivatives | |
IT244062Y1 (en) | DENTAL DEVICE TO COMPARE AND DETERMINE THE ASPECTOCROMATIC OF DENTAL PROSTHESES | |
NO962468D0 (en) | Preparation and use of nutrient granules | |
NO952301D0 (en) | Preparation and use of nutrient granules | |
FR2797445B1 (en) | ASCIDIDEMINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS | |
KR950022344U (en) | Sowing device capable of line sowing and point sowing | |
IT240030Y1 (en) | FIELD AND PLANT DEFOLIATOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |